Solutions
Circulating Tumor Cell Clinical Research

CTCs in Clinical Research


RareCyte enables practical deployment of circulating tumor cell (CTC) and rare cell-based liquid biopsy with instrumentation and consumables that provide an exquisitely sensitive, accurate, reproducible, and transparent workflow from blood collection to single cell isolation.

  • Unbiased, reproducible, highly sensitive, and specific rare cell detection
  • Scalable, high-capacity platform with workflow breakpoints, including slide banking, that enable multi-site execution
  • Deploy through our global contract research organization (CRO) network or in your own lab
  • Utilize cancer-specific panels or Developer panels for CTC biomarker analysis
  • Custom assay and companion diagnostics co-development through our Precision Biology Services
Five-cell circulating tumor cell cluster expressing drug target from a clinical research study participant
Five-cell circulating tumor cell cluster expressing drug target from a clinical research study participant. Cytokeratin (red) / EpCAM (magenta) / Drug target (green) / CD45 (yellow) / nuclei (blue)

WEBINAR: Analytical Validation of CTC Enumeration using the RareCyte Platform and Implementation in a Global Clinical Trial

Learn how the RareCyte platform for CTC analysis was validated in the Clinical Diagnostics Lab (CAP accredited CLIA Lab) at Eli Lilly and the platform added to a global clinical trial for further evaluation in collaboration with a CRO.

Speakers:

  • Jeff Fill MBA, MT(ASCP)
    Senior Director, Diagnostic and Experimental Pathology, Lilly Research Laboratories, Eli Lilly and Company
  • Arturo Ramirez PhD
    Director of Oncology, RareCyte Inc.

VIEW THE WEBINAR



Rare-cell applications for clinical research

RareCyte Liquid Biopsy technology is compatible with a broad range of sample types. This technology has been utilized across key research and clinical applications, from rare cell dentification to companion diagnostics development.

Applications

RarePlex® Assays: Design and Analytical Validation

Assay Design and Analytical Validation Presented by Dr. Tad George, SVP Biology R&D. RarePlex Assays are sensitive, specific, and reproducible assays for CTC detection and biomarker expression. Watch this video to gain insight into the principles RareCyte applies to its assay design and validation process.



Biomarker detection and exploration

Up to two additional channels are available for target biomarker assessment using validated assay kits or using a kit that allows insertion of user-defined markers. RareCyte also provides precision biology services to develop custom biomarker assays for CTCs and a range of other cell types including immune cells, circulating fibroblasts and circulating fetal cells.

RarePlex® Panel and Developer Assays for CTC enumeration and characterization

RarePlex Panel and Developer Assays for CTC Enumeration and Characterization. Presented by Arturo Ramirez, Ph.D., Director of Oncology R&D. This 7 minute overview of RarePlex Panel Kits and Developer technology highlights available circulating tumor cell assays from RareCyte.

The image above shows CTCs identified as nucleated cells that express CK/EpCAM but not CD45. Upper row: breast assay using the RarePlex HER2/ER CTC Panel Kit. Middle row: prostate assay using the ARv7 CTC Panel Kit. Lower row: Developer Kit for AR. Developer Kits allow added flexibility to customize panels with up to two additional target biomarkers.